Eidos Therapeutics, Inc. (NASDAQ:EIDX) SVP Franco Valle sold 1,747 shares of the stock in a transaction on Tuesday, January 12th. The stock was sold at an average price of $125.45, for a total value of $219,161.15. Following the completion of the sale, the senior vice president now owns 1,500 shares in the company, valued at approximately $188,175. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NASDAQ EIDX opened at $120.98 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.10 and a current ratio of 11.10. The company has a market cap of $4.70 billion, a PE ratio of -45.65 and a beta of -0.26. The business has a 50-day simple moving average of $113.70 and a two-hundred day simple moving average of $69.99. Eidos Therapeutics, Inc. has a fifty-two week low of $28.39 and a fifty-two week high of $132.54.
Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings results on Thursday, October 29th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.08). The business had revenue of $0.13 million during the quarter. On average, sell-side analysts predict that Eidos Therapeutics, Inc. will post -2.9 earnings per share for the current fiscal year.
EIDX has been the topic of a number of recent analyst reports. Piper Sandler lowered Eidos Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 5th. ValuEngine downgraded Eidos Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, September 28th. BMO Capital Markets downgraded Eidos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 6th. SVB Leerink downgraded Eidos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, October 5th. Finally, Smith Barney Citigroup reaffirmed a “buy” rating on shares of Eidos Therapeutics in a research report on Wednesday, December 30th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $58.53.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Further Reading: What does an outperform rating mean?
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.